CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process.
Until August 2023, CervoMed was known as EIP Pharma Inc. EIP Pharma Inc is now a wholly-owned subsidiary of CervoMed.
We believe the neurodegenerative process, in the early stages, is primarily comprised of neuroinflammation-induced damage to synapses, which are the interconnections between nerve cells, or neurons. Our lead product candidate, neflamapimod, is currently in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke.
We have assembled a highly experienced leadership team to develop and commercialize innovative drug treatments for dementia with Lewy bodies, Alzheimer’s disease and other central nervous system disorders.